Information Provided By: 
Fly News Breaks for November 2, 2018
ALKS
Nov 2, 2018 | 07:34 EDT
Stifel analyst Paul Matteis removed any near-term credit for ALKS5461 from his model after a 3-20 advisory committee vote against substantial evidence of effectiveness in major depressive disorder. The advisory committee meeting firmed his view that the drug will not be approved during this review cycle, said Matteis, who keeps a Hold rating on Alkermes shares and lowered his price target to $40 from $44.
News For ALKS From the Last 2 Days
There are no results for your query ALKS
